Cargando…
Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
BACKGROUND: Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in castration‐resistant prostate cancer (CRPC) with...
Autores principales: | Hyväkkä, Anniina, Kääriäinen, Okko‐Sakari, Utriainen, Tapio, Löyttyniemi, Eliisa, Mattila, Kalle, Reinikainen, Petri, Sormunen, Jorma, Jääskeläinen, Minna, Auvinen, Päivi, Minn, Heikki, Sundvall, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972699/ https://www.ncbi.nlm.nih.gov/pubmed/36156455 http://dx.doi.org/10.1002/cam4.5262 |
Ejemplares similares
-
Radium 223 dichloride for prostate cancer treatment
por: Deshayes, Emmanuel, et al.
Publicado: (2017) -
Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA
por: Sartor, Oliver, et al.
Publicado: (2016) -
Analysis of Unusual Adverse Effects After Radium-223 Dichloride
Administration
por: Frantellizzi, Viviana, et al.
Publicado: (2020) -
Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
por: Suominen, Mari I., et al.
Publicado: (2021) -
Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)